Navigation Links
Shire plc: Board Changes
Date:12/13/2007

BASINGSTOKE, England and PHILADELPHIA, December 13 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces its Board succession plans. Dr James H Cavanaugh (age 70) will retire as Non-Executive Chairman; Matthew Emmens (56) will succeed him as Non-Executive Chairman. Angus Russell (51) will be appointed Chief Executive.

These Board changes will become effective at Shire's AGM in June 2008. Also, at that time, David Kappler will be appointed as Deputy Chairman in addition to his existing role as Senior Independent Director. These appointments have the unanimous support of the Directors.

James Cavanaugh has been Chairman of Shire since 1999 and, on retiring, will have been a member of the Board for 11 years.

Matthew Emmens has 34 years of industry experience and since joining Shire in 2003, has successfully led the Company through a period of significant strategic development, including a number of important M&A transactions. This has created a leading global specialty biopharmaceutical company with a well developed and diversified product portfolio, an excellent management team and a strong corporate culture. Matthew Emmens also has valuable non-executive Board experience in his continuing roles on the Boards of Incyte Corporation (member of Audit Committee) and Vertex Pharmaceuticals Inc. (member of the Science and Technology and Governance committees).

Matthew Emmens' successor, as Chief Executive, will be Angus Russell, who has been Chief Financial Officer (CFO) since 1999 and who has also been instrumental in Shire's development in recent years. Angus Russell is well qualified for his new position with eight years experience at Shire as CFO and Executive Board Director and 27 years experience in the pharmaceutical industry including working for ICI, Zeneca and AstraZeneca in finance, strategy and marketing. Throughout his t
'/>"/>

SOURCE Shire PLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. KGI Elects Three New Members to Board of Trustees
8. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
9. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. BioLife Solutions Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and segments ... revenue. The Automatic patient billing market in Asia is ... at a developing CAGR of 7.2% from 2013 to ... Automatic patient billing market, to get an idea of ... of the segmentation of this market in the same ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
(Date:10/18/2014)... The “Human Insulin Market- by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... Kevin W. Sharer, chairman and chief executive officer of Amgen ... plan to retire from the Company at the end of ... an orderly transition process, Sharer will step down as CEO ... Company,s Board of Directors until December 31, 2012, at which ...
... OAKS, Calif., Dec. 15, 2011  Amgen (NASDAQ: AMGN ... $0.36 per share dividend for the first quarter of 2012. ... the previous two quarters. The dividend will be paid on ... the close of business on Feb. 15, 2012.  ...
... 15, 2011 Prolong Pharmaceuticals today announced ... spearhead the firms, engineering and facilities planning ...   Having previously directed the construction of the ... Grange Castle facility in Dublin, Ireland, Flachmeyer is ...
Cached Biology Technology:Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3Amgen Announces 2012 First Quarter Dividend 2Amgen Announces 2012 First Quarter Dividend 3Prolong's Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran 2
(Date:10/18/2014)... of patients with undiagnosed, suspected genetic conditions, a certain ... higher molecular diagnostic yield than traditional molecular diagnostic methods, ... The study is being released to coincide with the ... sequencing, which sequences the protein­coding region of the genome ... in a cell or organism), has been rapidly applied ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... National Oceanic and Atmospheric Administration, and the co-trustees for ... announced today they have started the injury assessment and ... a legal process to determine the type and amount ... to natural resources and their human uses as a ...
... Troy, N.Y. The purification of drug components ... is particularly true of drugs that utilize proteins, which ... impurities. Scientists within the Center for Biotechnology and Interdisciplinary ... magnetic resonance (NMR) to understand and improve an important ...
... The National Institute of Neurological Disorders and Stroke (NINDS), ... two new sites as part of the Morris K. Udall ... grants will provide a five-year investment totaling more than $16 ... for Medical Research in Manhasset, N.Y. NINDS ...
Cached Biology News:Resource restoration planning process begins for BP/Deepwater Horizon oil spill 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 3Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3NINDS awards new Udall Centers for Parkinson's Disease Research 2NINDS awards new Udall Centers for Parkinson's Disease Research 3